--- title: grant2 --- [![Small Batch Manufacturing for Rare Diseases and Oncology](https://events.pharm-int.com/hs-fs/hubfs/Pharmaceutics-International.png?width=1423&height=427&name=Pharmaceutics-International.png "Small Batch Manufacturing for Rare Diseases and Oncology")](http://pharm-int.com) # Introducing a $100,000 Grant for Project Funding Contribution for Emerging Drug Therapies ![cmo leadership awards](https://events.pharm-int.com/hs-fs/hubfs/cmo%20leadership%20awards.jpg?width=496&name=cmo%20leadership%20awards.jpg) As business leaders we have learned to see change as something positive, embracing it and associating it with transformation, advancement, and innovation. That’s when change is generated from within our organizations. However, when change comes unexpectedly from external sources outside of our control, it is unwelcome, disruptive, and limiting. The COVID-19 pandemic has forced change upon us in ways that have upset many of our plans. According to a [survey of biotech companies](https://www.biocentury.com/article/305012?customType=sResults_%2Fsearch%2Fsmall%2520biotechs%2520tighten%2520belts&kwh=small%20biotechs%20tighten%20belts%3C%7C%3Esmall%3C%7C%3Etighten%3C%7C%3Ebiotechs%3C%7C%3Ebelts) by Biocentury and investment management firm Sanford C. Bernstein1, most of the emerging biopharma companies do not have the required funding on hand to fuel the work to advance their therapeutic projects. Sadly, over 90% stated that due to the grim news from funding sources, they would be scaling back their plans and reducing their valuations. The reality is that these development pipelines aren’t simply projects. Lack of funding doesn’t just end the life of a project. Each of these projects represents therapy in development, a promising treatment, or even a cure, for a group of patients suffering from a disease or illness. For these patients, lack of funding represents lost hope. At Pii, we want to do something about it! That is why we are introducing the offer of a $100,000 contribution to your promising early-stage drug therapy. If your emerging therapy meets Pii’s requirements, we will provide a $100,000 credit to work performed at Pii. That’s right, we will deduct $100,000 from the cost of our work, all of which will be performed at our campus in Hunt Valley, MD We can support: - Biologics and Vaccine fill finish for clinical trial manufacturing (CTM), as well as, formulation & process development - Projects for COVID-19 treatments and vaccines in clinical development - New chemical entities (NCE) and new biological entities (NBE) requiring formulation and process development, as well as, CTM - Clinical Trial Supplies for small molecules, biologics and vaccines Begin your application process here   **Fill out this form in detail to apply for Pii First-in-human $100,000 Grant - Project Funding.**   Footnote 1. Biocentury and investment management firm Sanford C. Berstein, surveyed 106 biotech companies on COVID-19’s impact on their businesses. The results were published by Biocentury on April 25th, 2020. # Your website. Your blog. Your HubTheme. Blog subscribers get email updates daily, weekly, or monthly. Automagically. # About Us Use this little footer to reinforce your message about who you are and why people love working with you. And since this is a global module, you only have to edit it once to make the changes across every page it appears on. [Learn More](https://www.hubspot.com) # Links # Contact Us 410-584-0001 [yourname@company.com](mailto:yourname@company.com) 10819 Gilroy Road Hunt Valley, MD 21031 Copyright 2026 | Designed with by [HubSpot](https://www.hubspot.com)